Company Profile
Arcus Biosciences Stock Price, News & Catalysts
- Ticker:
- RCUS
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
25.23 USD (-2.32%)
Close
Last updated: October 1, 2026
3.08B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, RCUS closed down 2.32% at $25.23. No new same-company headline was identified in the current news window.
Company overview
Clinical-Stage Oncology and Immunology Company
Arcus Biosciences develops differentiated medicines for cancer and immune-mediated diseases. Its research model combines internally discovered molecules, biomarker-driven clinical development, and collaborations that can broaden the number and scale of combination studies.
Casdatifan Kidney Cancer Franchise
Casdatifan is an oral HIF-2α inhibitor being developed as a potential backbone therapy for clear-cell renal cell carcinoma. Arcus is studying the molecule as monotherapy and in combinations with zimberelimab, cabozantinib, and other agents across first-line, second-line, and later-line settings.
Quemliclustat in Pancreatic Cancer
Quemliclustat is a small-molecule CD73 inhibitor designed to reduce immunosuppressive adenosine in the tumor microenvironment. The program has advanced into the Phase 3 PRISM-1 study in metastatic pancreatic cancer in combination with chemotherapy.
Checkpoint and Combination Capabilities
Zimberelimab, an anti-PD-1 antibody, supports Arcus-controlled immuno-oncology combinations and may reduce dependence on externally sourced checkpoint inhibitors. The company also uses partnerships, including its alliance with Gilead, to fund and execute broad late-stage development programs.
Emerging Immunology Pipeline
Arcus is extending its discovery platform beyond oncology through AB102, an MRGPRX2-targeting antibody for mast-cell-driven diseases, and an oral TNF inhibitor. These programs add allergic and inflammatory disorders to a pipeline historically centered on solid tumors.
Future catalysts
- Multiple ARC-20 casdatifan datasets in renal cell carcinoma during the second half of 2026, including first-line combinations, second-line casdatifan plus cabozantinib, and late-line monotherapy follow-up.
- Initiation of the Phase 3 PEAK-20 casdatifan study by year-end 2026.
- Completion of enrollment in the Phase 3 PEAK-1 casdatifan study by year-end 2026.
- Phase 3 PRISM-1 results for quemliclustat in metastatic pancreatic cancer in the first half of 2027.
- Initial clinical proof-of-concept data for AB102 in mast-cell-driven disease around mid-2027.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Arcus Biosciences (RCUS)?
Arcus Biosciences (RCUS) most recently closed at 25.23 USD, a -2.32% move versus the previous session.
What is the market cap of Arcus Biosciences (RCUS)?
Arcus Biosciences currently has a market capitalization of 3.08B USD on BioPharmSignal.
What does Arcus Biosciences do?
Clinical-Stage Oncology and Immunology Company Arcus Biosciences develops differentiated medicines for cancer and immune-mediated diseases. Its research model combines internally discovered molecules, biomarker-driven clinical development, and collaborations that can broaden the number and scale of combination studies. Casdatifan Kidney Cancer...
On which exchange is RCUS stock listed?
Arcus Biosciences (RCUS) is associated with NYSE, United States, Biopharma.
What is HIF-2?
Casdatifan Kidney Cancer Franchise Casdatifan is an oral HIF-2α inhibitor being developed as a potential backbone therapy for clear-cell renal cell carcinoma.
Which conditions is Arcus Biosciences targeting with HIF-2?
Arcus Biosciences is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does Arcus Biosciences describe recent progress with HIF-2?
Multiple ARC-20 casdatifan datasets in renal cell carcinoma during the second half of 2026, including first-line combinations, second-line casdatifan plus cabozantinib, and late-line monotherapy follow-up. Initiation of the Phase 3 PEAK-20 casdatifan study by year-end 2026. Completion of enrollment in the Phase 3 PEAK-1 casdatifan study by year-end 2026....
What is PRISM-1?
The program has advanced into the Phase 3 PRISM-1 study in metastatic pancreatic cancer in combination with chemotherapy.